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Abstract
Introduction: Recently we reported that insulin receptor substrate 1 (IRS-1), classically an adaptor protein for the
insulin-like growth factor type I receptor (IGF-IR), associates with the epidermal growth factor receptor in oestrogen
receptor (ER)-positive (ER+) tamoxifen-resistant breast cancer cells. In this study, we examined whether IRS-1 also
associates with another erbB receptor family member, erbB3, and what impact this might have on IGF-IR signalling
in three ER+ breast cancer cell lines.
Methods: Immunoprecipitation and Western blot analysis were utilised to examine the potential association
between erbB3 and IRS-1 in MCF-7, T47D and BT-474 cells in the absence and presence of the erbB3/4 ligand
heregulin b1 (HRGb1). Subsequently, the impact of a selective IGF-IR/IR inhibitor 4-anilino-5-bromo-2-[4-(2-hydroxy-
3-(N, N-dimethylamino)propoxy)anilino]pyrimidine on this association and HRGb1 signalling was assessed in these
cell lines. Immunohistochemical analysis of a small cohort of ER+ breast cancer patient samples was also
performed to determine the potential clinical relevance of this novel interaction.
Results: Immunoprecipitation and Western blot analysis revealed an interaction between erbB3 and IRS-1 in MCF-
7, T47D and BT-474 cells, with HRGb1 significantly enhancing this recruitment and promoting IRS-1
phosphorylation at Y612. IRS-1 participates in erbB3 signalling in MCF-7 and T47D cells as IRS-1 knockdown
impaired HRGb1 signalling. Importantly, recruitment of IRS-1 by erbB3 reduced IRS-1 association with IGF-IR in
MCF-7 and T47D cells, whilst blockade of IGF-IR-enhanced erbB3-IRS-1 interaction and sensitised both cell lines to
HRGb1, allowing HRGb1 to override IGF-IR blockade. Consequently, suppression of IRS-1 signalling enhanced the
effects of IGF-IR inhibition in these cells. This novel interaction may have clinical relevance, as
immunohistochemical analysis of a small ER+ breast tumour series revealed significant positive correlations
between phosphorylated IRS-1 Y612 expression and total erbB3, phosphorylated Akt and Ki-67 expression.
Conclusions: IRS-1 can be recruited to IGF-IR and erbB3 in ER+ breast cancer cells, and this provides an adaptive
resistance mechanism when these receptors are targeted individually. Consequently, cotargeting IGF-IR and either
erbB3 or IRS-1 should prove to be a more effective strategy for the treatment of ER+ breast cancer.
Keywords: breast cancer, erbB3, IRS-1, IGF-IR, resistance
* Correspondence: hutchesonir@cf.ac.uk
4Department of Pharmacology, Radiology & Oncology, Cardiff University,
School of Medicine, Heath Park, Cardiff, CF14 4XN, UK
Full list of author information is available at the end of the article
Knowlden et al. Breast Cancer Research 2011, 13:R93
http://breast-cancer-research.com/content/13/5/R93
© 2011 Knowlden et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Introduction
There is strong experimental and clinical evidence impli-
cating the insulin-like growth factor type I receptor (IGF-
IR) in breast cancer development and growth [1-3]. The
IGF-IR, which belongs to a family of receptor tyrosine
kinases that includes the insulin receptor (IR), has been
found to be expressed in a high percentage of breast
tumours, where its expression is positively correlated
with oestrogen receptor (ER) status and is usually coex-
pressed with markers of a better overall prognosis
[2,4-6]. Expression of the IGF-IR has also been demon-
strated in the majority of ER+ breast cancer cell lines
[7,8]. Indeed, in MCF-7 cells, IGF-IR has been shown not
only to be a key receptor in mediating hormone-sensitive
growth but also to engage in significant cross-talk with
ER [9,10]. Importantly, this leads to synergistic interac-
tions between ER and IGF-IR signalling to promote effi-
cient growth responses [2].
However, conversely, increased expression and activa-
tion of IGF-IR and its associated downstream signalling
components have also been reported in some clinical
breast cancers and have been linked to disease progres-
sion and recurrence [11,12]. On the basis of these data,
IGF-IR has been identified as a potential therapeutic tar-
get for the treatment of breast cancer [13]. Activation of
the IGF-IR promotes binding of insulin receptor sub-
strate (IRS) members, a family of structurally related
adaptor molecules which have classically been identified
as key signalling intermediates of the IR and IGF-IR [14].
Binding results in phosphorylation of their carboxyl ter-
mini at multiple tyrosine residues, and these phosphotyr-
osine residues provide docking sites for the recruitment
of key signalling pathways, such as the mitogen-activated
protein kinase (MAPK)/extracellular signal-regulated
kinase 1/2 (ERK1/2) and phosphatidylinositol 3-kinase
(PI3K) pathways [15]. These signalling cascades can med-
iate mechanisms underlying tumour growth and progres-
sion, implicating a potential role for IRS members in
oncogenesis [1,15-18]. Indeed, IRS-1 has been reported
to be overexpressed and constitutively phosphorylated in
breast tumours [18,19], and high expression of this adap-
tor protein has been associated with lymph node metas-
tases and poor patient prognosis [11,20,21]. Furthermore,
IRS-1 and IRS-2 have been implicated in the regulation
of proliferation, survival and metastatic potential in a
range of breast cancer cell lines [17].
However, there is now increasing evidence that IRS-1 is
not restricted to binding to IR/IGF-IR but is also capable
of associating with a variety of other signalling-related pro-
teins [17]. One such protein is the epidermal growth factor
receptor (EGFR), a member of the erbB receptor tyrosine
kinase family also comprising erbB2, erbB3 and erbB4 and
which has been shown to play a central role in driving
both de novo and acquired anti-hormone-resistant growth
and invasion in breast cancer [22-25]. Evidence of an
EGFR-IRS-1 interaction arises from reports by Fujioka and
colleagues [26,27], who reported that the phosphorylated
NPXY motifs in activated IR and IGF-IR to which IRS
molecules bind are also present in the C-terminus region
of activated EGFR and were indispensable for EGF-
induced IRS-1 tyrosine phosphorylation in EGFR-trans-
fected CHO cells [27]. Furthermore, a potential interaction
between EGFR and IRS-1 has been predicted on the basis
of the binding of peptides, representing the physical sites
of EGFR tyrosine phosphorylation, to protein microarrays
comprising all Src homology 2 and phosphotyrosine bind-
ing domains encoded in the human genome [28]. Recently,
we provided strong evidence that IRS-1 can function as a
key signalling intermediate for EGFR, a receptor that
drives the growth of a tamoxifen-resistant MCF-7 breast
cancer cell line [29]. In these cells, we showed that IRS-1
physically complexes with EGFR and is preferentially
phosphorylated on Y896, a Grb2-binding/MAPK recruit-
ment site [15]. Moreover, EGFR was the dominant recrui-
ter of IRS-1, which thus served to limit the availability of
IRS-1 to associate with IGF-IR in these cells and, as a
result, suppressed IGF-IR signalling via this receptor.
Other erbB receptors are also prevalent in breast cancer,
and their interplay with IRS-1 remains unknown. Of note,
we have previously shown [30] that erbB3 is commonly
expressed in clinical breast tumours alongside one of its
ligands, heregulin b1 (HRGb1). Interestingly, erbB3 also
possesses the NPXY motifs recognized by IRS proteins
[31] and as such may bind IRS-1 in breast cancer cells.
Indeed, such an association has again been predicted on
the basis of protein microarray studies [28]. A role for
erbB3 in breast cancer has only recently become appre-
ciated [32,33], with overexpression of erbB3 shown to be
positively associated with metastasis [34], increased histo-
logical grade [35] and tumour recurrence [36]. There is
also growing awareness of the importance of the erbB2/
erbB3 heterodimer in breast cancer progression. Heterodi-
mers between these two receptors have been shown to
form the most potent mitogenic and transforming recep-
tor complex in vitro [37], and coexpression of erbB2 and
erbB3 have been shown to be significantly associated with
decreased survival in breast cancer patients [38]. Interest-
ingly, erbB3 signalling has also been implicated in mediat-
ing resistance to IGF-IR-targeted agents in hepatocellular
carcinoma cells [39], but whether it plays a similar role in
breast cancer remains to be determined. In the present
study, using a panel of ER+ breast cancer cell lines, we
examined for the first time whether IRS-1 can contribute
to erbB3 signalling in breast cancer and what impact this
may have on IGF-IR signalling. We show that IRS-1 is
recruited to erbB3 following HRGb1 treatment in these
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cells and demonstrate that this novel interaction can serve
to reduce the association between IRS-1 and IGF-IR and
inhibits signalling via this receptor. We show in turn that
suppression of IGF-IR by the use of a tyrosine kinase inhi-
bitor and siRNA technology can promote erbB3 down-
stream signalling by reinforcement of erbB3 interplay with
IRS-1. This provides a potential novel resistance signal,
which, when targeted, may generate more effective inhibi-
tion of cell growth compared to IGF-IR treatment alone.
Materials and methods
Cell culture
MCF-7 cells (a gift from AstraZeneca Pharmaceuticals,
Cheshire, UK) and T47D cells (American Type Culture
Collection (ATCC), Manassas, VA, USA), which are both
nonamplified erbB2 breast cancer cell lines, were grown in
RPMI medium containing 5% FCS and glutamine (4 mM).
Both cell lines were maintained at 37°C in a humidified 5%
CO2 atmosphere. BT-474 over amplified erbB2 breast can-
cer cells (ATCC) were grown in RPMI medium containing
10% FCS and glutamine (4 mM).
Experimental procedures
The cell lines were grown to 70% confluence prior to
transfer into phenol red/steroid-and serum growth fac-
tor-free dendritic cell conditioned medium (Biosynergy
Europe, Cambridge, UK) for 24 hours followed by expo-
sure for up to 20 minutes to either 0.1 to 10 ng/ml
HRGb1 or 10 ng/ml IGF-I in 10 mM acetic acid/0.1%
BSA or appropriate vehicle control. To examine the
effects of pharmacological blockade of IGF-IR, cells were
incubated in phenol red-free (white) RPMI medium
supplemented with 5% FCS and either the IGF-IR/IR
tyrosine kinase inhibitor 4-anilino-5-bromo-2-[4-(2-
hydroxy-3-(N, N-dimethylamino)propoxy)anilino]pyrimi-
dine (ABDP) (1 μM in dimethyl sulphoxide, AstraZeneca,
Macclesfield, UK) [40] or appropriate vehicle control for
1 to 2 days. All experiments were performed at least
three times. Cells were then lysed to measure protein
expression.
siRNA studies
Dharmacon SMARTpool siRNA Design specific for IRS-1
(IRS si), erbB3 (3 si) or IGF-IR (IGF si; all 20 mM, Dhar-
macon RNAi Technologies, Lafayette, CO, USA) were
mixed with DharmaFECT 1 transfection reagent (lipid;
Dharmacon RNAi Technologies) at a ratio of 10 μl of
siRNA to 1 μl of lipid and incubated at room temperature
for 20 minutes. The mix was added to the cells, which
were maintained in white RPMI medium containing 5%
FCS to give a final siRNA concentration of 100 nM per
dish. Control experiments consisted of transfection with
the ON-TARGETplus Nontargeting siRNA control pool
(100 nM; Dharmacon RNAi Technologies), medium only
(nontransfected cells) or lipid. All experimental arms
were set up in duplicate. Cells were incubated in growth
medium containing either IRS si, 3 si, IGF si or control
(C si) (100 nM for each) for 4 days prior to treatment
with either 10 ng/ml HRGb1 or vehicle alone for 5 min-
utes. To examine the effect of IRS-1 knockdown and
IGF-IR blockade, cells were incubated in medium con-
taining either 100 nM C si, 100 nM IRS si, 1 μM ABDP
or a combination of these treatments prior to a 5-minute
incubation with HRGb1 (10 ng/ml). The cells were then
lysed, and protein extracts were examined by Western
blot analysis.
Immunoprecipitation and Western blot analysis
Fresh cell lysates containing 500 μg of protein were immu-
noprecipitated using 1 μg of specific antibody as described
previously [24]. Protein samples from either immunopreci-
pitation or total cell lysates (20 to 50 μg) were separated
on a 7.5% polyacrylamide gel and then transblotted onto
nitrocellulose membrane as described previously [24]. The
antibodies used were directed against total EGFR (SC-03),
total erbB2 (SC-284), total erbB3 (SC-285), total IGF-IR
(SC-712), total IRS-1 (SC-7200; Insight Biotechnology Ltd,
Wembley, UK), total and phosphorylated Akt YS473,
ERK1/2 and phosphorylated c-erbB3 Y1289 (Cell Signaling
Technology, Hitchin, UK), phosphorylated EGFR (Y1068),
phosphorylated IRS-1 (Y612 and Y896; BioSource Interna-
tional, Camarillo, CA, USA), b-actin (Sigma-Aldrich,
Dorset, UK) and specific phosphorylated IGF-IR Y1316 (a
kind gift from AstraZeneca, Macclesfield, UK). The Wes-
tern blots were then scanned by densitometry to provide
data for semiquantification. Each experiment was per-
formed at least three times with representative gels shown
in figures.
Cell proliferation studies
Cells were seeded at 40, 000 cells per well overnight in
phenol red-free RPMI medium supplemented with 5%
FCS and then incubated in fresh medium containing 0.1
to 1 μM ABDP, 10 ng/ml HRGb1, vehicle control or a
combination of these agents for 4 days. Cell population
growth was evaluated by means of trypsin dispersion of
the cell monolayers, and cell number was measured
using a COULTER COUNTER (Beckman Coulter (UK)
Ltd, High Wycombe, UK). All experiments were per-
formed in triplicate.
Clinical series
A small historical series of 50 primary tumours were
excised from ER+ patients with histologically proven
breast cancer who had presented for surgery at Notting-
ham City Hospital (Nottingham, UK) from 1984 to 1987.
Representative tissue samples from these tumour samples
were fixed routinely in 4% formal saline and embedded in
Knowlden et al. Breast Cancer Research 2011, 13:R93
http://breast-cancer-research.com/content/13/5/R93
Page 3 of 17
paraffin. No patient had previously received any form of
adjuvant endocrinological or cytotoxic therapy. The use
of these samples for research purposes, without the
requirement of further patient informed consent, was
approved by Nottingham Research Ethics Committee 2
under the title ‘Development of a molecular genetics clas-
sification of breast cancer’ (C2020313).
Immunocytochemical assays
Immunocytochemical assays for phosphorylated Akt, Ki-
67 and total erbB3 and specific phosphorylated IGF-IR
Y1316 were performed on 50 primary ER+ breast
tumours as previously described [6,30,41] and the clini-
copathological parameters for the clinical set of these
tumours are as shown (Additional file 1, Table S1). For
the detection of phosphorylated IRS-1 Y612, paraffin wax
sections from each tumour sample were dewaxed using
xylene treatment and then rehydrated through graded
ethanols to PBS. Endogenous peroxidases were destroyed
by immersing the sections in 3% hydrogen peroxide pre-
pared in methanol for 5 minutes, followed by rinsing
with distilled water for 5 minutes. Antigen retrieval was
achieved by pressure cooking the slides in 0.01 M sodium
citrate buffer, pH 6.0, for 4 minutes. Slides were then
immersed in slowly running tap water for 10 minutes
before being transferred to PBS for 5 minutes. Sections
were blocked in 1% l BSA for 5 minutes prior to incuba-
tion overnight at 37°C in anti-phosphorylated IRS-1 Y612
rabbit primary antibody diluted 1:50 in PBS. Sections
were washed for 3 minutes in PBS, washed twice for 5
minutes in 0.02% PBS-Tween 20 and then incubated for
2 hours at room temperature in a peroxidase-labelled
polymer secondary antibody EnVision Kit (Dako Ltd, Ely,
UK). Slides were then washed for 3 minutes in PBS,
washed twice for 5 minutes in 0.02% PBS-Tween 20 and
incubated for 10 minutes at room temperature in EnVi-
sion DAB chromogen solution (diaminobenzidine; Dako
Ltd). Slides were then rinsed twice for 2 minutes in
distilled water, incubated in 0.5% methyl green for 25
seconds as a counterstain, rinsed in distilled water and
allowed to air-dry before DPX mountant (a mixture of
distyrene, a plasticizer and xylene) was applied. Com-
bined cytoplasmic and plasma membrane staining inten-
sity and percentage positivity were assessed by HScore
analysis as described previously [41]. Expression of phos-
phorylated membrane and cytoplasmic IRS-1 Y612 has
previously been verified by immunocytochemistry in ER+
breast cancer cell lines [29].
Statistics
For immunocytochemical analysis of clinical material,
Hscores were compared using Spearman’s rank-correlation
and Mann-Whitney U tests for nonparametric data. For
experimental growth studies, overall differences between
the control and treatment groups were determined by ana-
lysis of variance with post hoc t-tests with the Bonferroni
adjustment factor. A two-sided t-test was performed on
the densitometry values obtained following Western blot
analysis. Differences were considered significant at the P ≤
0.05 level.
Results
Heregulin b1 promotes phosphorylation of insulin
receptor substrate 1 in MCF-7, T47D and BT-474
oestrogen receptor-positive breast cancer cells
Western blot analysis demonstrated that 5-minute HRGb1
stimulation promoted EGFR, erbB3, erbB2 and EGFR
phosphorylation and activation of the downstream signal-
ling components Akt and ERK1/2 in MCF-7, T47D and
BT-474 breast cancer cells, as shown in Figure 1a. Inter-
estingly, HRGb1 also promoted phosphorylation of IRS-1
at Y612 and at Y896 in all cell lines, but less dramatically
in the BT-474 cells (Figure 1b). Treatment of HRGb1 had
no effect on either specific IGF-IR Y1316 phosphorylation
or total IGF-IR protein expression levels in these cell lines,
whilst, as expected, 10 ng/ml IGF-I stimulation promoted
IGF-IR phosphorylation (Figure 1c).
Insulin receptor substrate 1 associates with erbB
receptors in MCF-7, T47D and BT-474 cells
Immunoprecipitation and Western blot analysis were per-
formed to examine whether IRS-1 associates with erbB
receptors, notably erbB3, in the ER+ breast cancer cell
lines. Western blot analysis demonstrated an interaction
between erbB3 and IRS-1 under both basal and HRGb1-
primed growth conditions in MCF-7 cells (Figure 2a). The
specificity of the anti-IRS-1 and anti-erbB3 antibodies
used in these studies was confirmed using rabbit immuno-
globulin G antibodies (Figure 2a). A HRGb1 time course
was also performed in MCF-7 cells, and maximum IRS-1
Y612 and Y896 phosphorylation levels were observed after
just 2 minutes treatment time. This was sustained for up
to 20 minutes (data not shown). Immunoprecipitation per-
formed over this time span clearly showed increased asso-
ciation between IRS-1 and erbB3 following HRGb1
treatment (Figure 2a). IRS-1 was also shown to associate
with both EGFR and erbB2 under basal growth conditions,
and these associations were enhanced following HRGb1
treatment (Figure 2a). Similar findings were also observed
for T47D cells, as shown in Figure 2b. Moreover, HRGb1
stimulation also promoted a significant decrease in asso-
ciation between IRS-1 and IGF-IR in both the MCF-7 and
T47D cells (Figure 2c), and densitometric analysis revealed
this reduction to be statistically significant in both cell
lines (P ≤ 0.01 (n = 3) and P ≤ 0.05 (n = 3), respectively)
(Figure 2d). However, although BT-474 cells showed an
association between IRS-1 and erbB3 under basal growth
conditions, this was not increased further following
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Figure 1 Western blot analysis. (a) Phosphorylated and total epidermal growth factor receptor (EGFR), erbB2, erbB3, Akt and extracellular-
signal regulated kinase 1/2 (ERK1/2) and (b) phosphorylated and total insulin receptor substrate 1 (IRS-1) protein expression following treatment
of MCF-7, T47D and BT-474 breast cancer cells with either heregulin b1 (HRGb1) (10 ng/ml) or vehicle control for 5 minutes. (c) Western blot
analysis of phosphorylated and total insulin-like growth factor type I receptor (IGF-IR) protein expression following treatment of MCF-7, T47D and
BT-474 breast cancer cells with HRGb1 (10 ng/ml), IGF-I (10 ng/ml) or vehicle control for 5 minutes. Data are representative of three separate
experiments.
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Figure 2 Western blot showing erbB3, EGFR, erbB2 and insulin receptor substrate 1 protein expression. (a) Immunoprecipitation (IP)
with rabbit immunoglobulin G (IgG) (negative control), insulin receptor substrate 1 (IRS-1) or erbB3 antibody for MCF-7 cells treated with either
heregulin b1 (HRGb1) (10 ng/ml) or vehicle control for 5 minutes or up to 20 minutes, (b) immunoprecipitation with either IRS-1 or erbB3
antibody in T47D and BT-474 cells treated with either HRGb1 (10 ng/ml) or vehicle control for 5 minutes. (c) Western blot analysis of IGF-IR and
IRS-1 protein expression following immunoprecipitation with IRS-1 antibody in MCF-7, T47D and BT-474 cells treated with either HRGb1 (10 ng/
ml) or vehicle control for 5 minutes. (d) Densitometric analysis of the loss of IRS-1 association with IGF-IR following HRGb1 treatment in MCF-7
and T47D cells. The results are expressed as means ± standard errors of the mean of at least three separate experiments. The y-axis represents
arbitrary optical densitometric units. In MCF-7 cells * P ≤ 0.01 versus Control; In T47D cells * P ≤ 0.05 versus Control.
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HRGb1 treatment (Figure 2b). In addition, there was no
decrease in association between IGF-IR and IRS-1 follow-
ing HRGb1 stimulation in these cells (Figure 2c) and, as a
consequence, BT-474 cells were excluded from further
studies.
erbB3 siRNA knockdown reduces heregulin b1-induced
insulin receptor substrate 1 phosphorylation in MCF-7
and T47D cells
Western blot analysis demonstrated that both basal and
HRGb1-primed IRS-1 Y612 and Y896 phosphorylation
levels were markedly reduced following incubation of
MCF-7 and T47D breast cancer cells with siRNA-targeting
erbB3 protein expression. The reduction in IRS-1 Y612
and Y896 phosphorylation was found to be statistically sig-
nificant following densitometric analysis (P ≤ 0.01 (n = 3)
and P ≤ 0.01 (n = 3), respectively, for MCF-7; P ≤ 0.01
(n = 3) and P ≤ 0.001 (n = 3), respectively, for T47D cells)
(Figures 3b and 3c). Basal and HRGb1-primed Akt and
ERK1/2 phosphorylation levels were similarly inhibited by
the erbB3 siRNA treatment (Figure 3a), whilst total Akt,
ERK1/2 and b-actin protein levels remained constant fol-
lowing total erbB3 downregulation in both cell lines.
Insulin receptor substrate 1 siRNA knockdown reduces
heregulin b1-primed erbB3 signalling
Interestingly, the ability of HRGb1 to prime Akt phos-
phorylation was reduced substantially following incubation
of MCF-7 and T47D cells with siRNA-targeting IRS-1 pro-
tein expression as demonstrated by Western blot analysis
(Figure 4a). Moreover, this decrease in Akt phosphoryla-
tion was statistically significant following densitometric
analysis (P ≤ 0.01 (n = 3) and P ≤ 0.001 (n = 3) for MCF-7
and T47D cells, respectively) (Figures 4b and 4c). How-
ever, there was no obvious reduction in HRGb1-induced
ERK1/2 phosphorylation in these cells following IRS-1
protein downregulation. Total Akt, ERK1/2 and b-actin
protein levels remained constant.
Insulin-like growth factor type I receptor inhibition
facilitates insulin receptor substrate 1 association with
erbB3 and promotes heregulin b1-induced
phosphorylation of insulin receptor substrate 1 Y612 in
MCF-7 and T47D cells
We next examined whether recruitment of IRS-1 by erbB3
can provide a resistance mechanism to IGF-IR-targeted
therapy. A 24-hour treatment with the IGF-IR inhibitor
ABDP enhanced the sensitivity of MCF-7 and T47D cells
to HRGb1, with increased phosphorylation of IRS-1 Y612,
IRS-1 Y896, Akt and ERK1/2 apparent at lower concentra-
tions of this ligand (Figure 5a). These increases were not
due to increased IGF-IR activity, as specific phosphory-
lated IGF-IR levels were completely inhibited following
ABDP treatment. Densitometric analysis showed that the
increase in Akt phosphorylation was statistically significant
for both MCF-7 cells (P ≤ 0.05 (n = 3)) and T47D cells
(P ≤ 0.05 (n = 3)) at the 1 ng/ml HRGb1 concentration
(Figures 5b and 5c). The increased ERK1/2 phosphoryla-
tion observed in MCF-7 cells failed to reach statistical sig-
nificance (P = 0.06 (n = 3)) (Figure 5b), although
significance was reached for the T47D cells (P ≤ 0.05 (n =
3)) (Figure 5c). Total protein levels remained constant fol-
lowing IGF-IR inhibition in both cell lines. These results
were verified further in both cell lines using siRNA to spe-
cifically target IGF-IR (Additional file 2, Figure S1). Immu-
noprecipitation and Western blot analysis also revealed
that, following treatment of MCF-7 and T47D cells with
ABDP, there was a reduced association between IRS-1 and
IGF-IR and an enhanced association between IRS-1 and
erbB3, as shown in Figure 5d.
siRNA knockdown of insulin receptor substrate 1 reverses
the increased sensitivity to heregulin b1 observed
following insulin-like growth factor type I receptor
blockade in MCF-7 and T47D cells
The increase in HRGb1-induced Akt phosphorylation
observed following treatment of MCF-7 and T47D
breast cancer cells with the IGF-IR/IR inhibitor ABDP
for 24 hours was effectively blocked using siRNA speci-
fic to IRS-1 (Figure 6a). However, IRS-1 knockdown had
only a small effect on HRGb1-induced ERK1/2 phos-
phorylation, and it had no effect on total IGF-IR, Akt,
ERK1/2 and b-actin protein levels in both these cell
lines.
Growth inhibition by ABDP can be overcome by
heregulin b1 in MCF-7 and T47D cells
The growth of MCF-7 and T47D breast cancer cells was
significantly increased in the presence of HRGb1 (P ≤
0.001 (n = 3) and P ≤ 0.01 (n = 3), respectively) and signifi-
cantly reduced by approximately 50% in the presence of
either 0.1 μM ABDP in MCF-7 cells (P ≤ 0.001 (n = 3)) or
0.75 μM ABDP in T47D cells (P ≤ 0.001 (n = 3)) (Figures
6b and 6c). This inhibition in cell growth observed with
ABDP was potently and significantly overridden by treat-
ment of MCF-7 and T47D cells with 10 ng/ml HRGb1
(P ≤ 0.001 (n = 3) and P ≤ 0.01 (n = 3), respectively) as
shown in Figures 6b and 6c.
Phosphorylated insulin receptor substrate 1 Y612
expression positively correlates with erbB3 and insulin-
like growth factor type I receptor expression in oestrogen
receptor-positive clinical breast cancer material
Phosphorylated IRS-1 Y612 protein was expressed in the
majority of paraffin-embedded breast cancer clinical sam-
ples (range, 0 to 220; median, 61) as assessed by immu-
nocytochemical analysis, with immunostaining localised
predominantly at the plasma membrane, although some
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Figure 4 Western blot analysis. (a) Phosphorylated and total insulin receptor substrate 1 (IRS-1), Akt, extracellular-signal regulated kinase 1/2
(ERK1/2) and b-actin protein expression in MCF-7 and T47D cells incubated in medium supplemented with either lipid and control siRNA (C si)
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cytoplasmic staining was also observed (Figure 7a).
Immunocytochemical assays for phosphorylated Akt,
specific phosphorylated IGF-IR (Y1316), nuclear Ki-67
and total erbB3 were also performed as previously
described on the 50 primary ER+ breast tumours
[6,30,41], and the clinicopathological parameters for the
clinical set of these tumours are given in Additional file
1, Table S1. A Mann-Whitney U test was applied to
these samples to determine the relationships between
phosphorylated membrane IRS-1 Y612 immunostaining
(using a median HScore of 10 as a cutoff for positivity)
and total membrane and cytoplasmic erbB3, membrane
phosphorylated IGF-IR Y1316, membrane and cytoplas-
mic phosphorylated Akt and percentage of nuclear Ki-67
immunostaining HScore values. Interestingly, total mem-
brane and cytoplasmic erbB3 expression was significantly
higher in phosphorylated membrane IRS-1 Y612-positive
tumours than in phosphorylated membrane IRS-1 Y612-
negative tumours (P = 0.009 (n = 33)) (Figure 7b).
Further analysis also revealed that phosphorylated mem-
brane and cytoplasmic IRS-1 Y612-positive tumours
(median HScore cutoff of 61) expressed higher levels of
phosphorylated membrane IGF-IR Y1316 (P = 0.011 (n =
50)), phosphorylated membrane and cytoplasmic Akt
(P ≤ 0.001 (n = 50)) and nuclear Ki-67 (P = 0.022 (n =
40)) immunostaining than did phosphorylated membrane
and cytoplasmic IRS-1 Y612-negative tumours (not
shown). In addition, Spearman’s rank-correlation test
was applied to this group of ER+ patients. This analysis
confirmed the Mann-Whitney U test findings revealing
that phosphorylated membrane IRS-1 Y612 immunos-
taining positively correlated with immunostaining for
total membrane and cytoplasmic erbB3 (P = 0.015 (n =
33)) (Figure 7b). Significant positive correlations between
phosphorylated membrane and cytoplasmic IRS-1 Y612
and phosphorylated membrane IGF-IR (P = 0.025 (n =
50)), phosphorylated membrane and cytoplasmic Akt
(P = 0.001 (n = 50)) and nuclear Ki-67 (P = 0.007 (n =
40)) were also observed (not shown).
Discussion
IRS-1 is not restricted to binding to IR/IGF-IR but also has
the capacity to interact with a variety of other proteins
[21]. Recently, we reported that IRS-1 can interact with
EGFR, resulting in loss of recruitment of IRS-1 by IGF-IR
and reducing signalling via this receptor in an ER+, tamox-
ifen-resistant MCF-7 breast cancer cell line [29]. In the
present study, we examined whether IRS-1 can associate
with other erbB family members, notably erbB3, and
whether this has a direct impact on IGF-IR signalling in
three ER+ breast cancer cell lines (MCF-7, T47D and BT-
474) previously shown to express IRS-1 protein [42-44].
Initial characterisation of these cell lines showed that
EGFR, erbB2, erbB3 and associated downstream signalling
elements MAPK and Akt were activated following HRGb1
treatment, with this ligand having a more potent effect on
phosphorylation levels in MCF-7 and T47D cells that on
BT-474 cells. Interestingly, HRGb1 treatment also
increased levels of IRS-1 phosphorylation at both the Y612
and Y896 residues, with this effect being greater in MCF-7
and T47D cells than in the BT-474 cell line. The more
modest effect of HRGb1 priming of such activity in
BT-474 cells most likely reflects the fact that these cells
constitutively overexpress erbB2 and consequently have
higher basal phosphorylation levels of all these signalling
elements. As such, any increase in activity is harder to dis-
tinguish compared to the erbB2 low-expressing MCF-7
and T47D cell lines [45]. Using immunoprecipitation and
Western blot analysis, we confirmed that HRGb1-induced
phosphorylation of IRS-1 was a result of IRS-1’s complex-
ing with erbB3/EGFR and erbB3/erbB2 heterodimers in
both MCF-7 and T47D cells. The ability of erbB3 to het-
erodimerise with both EGFR and erbB2 in response to
HRGb1 stimulation explains the increased phosphoryla-
tion of IRS-1 at Y896 in these two cell lines. We have pre-
viously described the recruitment and phosphorylation of
IRS-1 at this tyrosine residue by EGFR/erbB2 heterodi-
mers in a tamoxifen-resistant MCF-7 breast cancer cell
line [29]. We have previously reported that phosphoryla-
tion of IRS-1 Y612 results from recruitment and activation
by IGF-IR. In the present study, however, HRGb1-induced
IRS-1 Y612 phosphorylation appeared to be IGF-IR-inde-
pendent. There was no effect of this ligand on IGF-IR
phosphorylation, as verified by the use of a specific
pY1316 IGF-IR antibody in these cell lines [40]. Indeed,
HRGb1 treatment reduced the association of IRS-1 with
IGF-IR in both cell lines. This leaves association of IRS-1
with erbB3 as the likely mediator of HRGb1-induced IRS-
1 Y612 phosphorylation in these cells.
It has previously been reported in other systems that
IRS-1-erbB3 interactions can occur, as erbB3 possesses
NPXY motifs within its C-terminal domain, like those
observed in IGF-IR/IR, which are recognized by IRS pro-
teins and would enable this adaptor molecule to poten-
tially bind to this receptor [31]. Furthermore, in a study of
the binding of peptides representing the physical sites of
erbB3 tyrosine phosphorylation to protein microarrays
comprising all Src homology 2 and phosphotyrosine bind-
ing domains encoded in the human genome, researchers
predicted a potential interaction between erbB3 and IRS-1
[28]. Importantly, our studies reveal that IRS-1 has a sig-
nificant functional role in erbB3 signalling in MCF-7 and
T47D cells, as erbB3 knockdown using siRNA potently
inhibited basal and HRGb1-induced IRS-1, Akt and ERK1/
2 phosphorylation, whilst IRS-1 siRNA similarly reduced
HRGb1-induced Akt and, to a modest degree, ERK1/2
activity in these cells. As ERK1/2 activity was not signifi-
cantly altered following IRS-1 knockdown, this would
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Figure 7 Immunocytochemical staining. (a) Phosphorylated insulin receptor substrate 1 (IRS-1) Y612, insulin-like growth factor type I receptor
(IGF-IR), Y1316, total erbB3, Akt and Ki-67 in paraffin-embedded primary clinical oestrogen-positive (ER+) breast cancer sections (original
magnification, ×40). (b) Representative boxplot and scatterplot showing statistically significant correlations between immunostaining HScore
values for phosphorylated membrane IRS-1 Y612 and total membrane and cytoplasmic erbB3 in the clinical ER+ breast cancer series.
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suggest that an IRS-1-independent mechanism underlying
HRGb1-induced ERK1/2 activity was at work in our cell
lines. Consequently, the remainder of our study focused
primarily on IRS-1 Y612/Akt phosphorylation, as this
appeared to be the IRS-1-dependent pathway in response
to HRGb1 in our cell models. In BT-474 cells, there was a
strong basal association between IRS-1 and erbB3, as
observed in immunoprecipitation studies, which could not
be enhanced further by exogenous ligand stimulation.
Again, this could be due to the high constitutive erbB2
activity present within these cells masking the exogenous
stimulatory effects of HRGb1 treatment. Moreover, IRS-1
itself may potentially be more freely available to interact
with erbB3 in these cells, as they have somewhat less IGF-
IR protein with which to associate compared to MCF-7
and T47D cells, as shown in this study and as shown else-
where previously [46]. As this HRGb1-induced association
between IRS-1 and erbB3 was not evident in the BT-474
cells, these cells were omitted from further study.
As mentioned previously, another interesting phenom-
enon noted in these studies is the finding that whilst
HRGb1 treatment enhanced erbB3-IRS-1 interactions, it
also promoted a decrease in the association between IRS-
1 and IGF-IR, an effect that was clearly apparent in the
MCF-7 and T47D cell lines. This finding suggests that
the enhanced physical interaction between erbB3 and
IRS-1 following HRGb1 treatment may serve to limit the
availability of IRS-1 to associate with IGF-IR, potentially
resulting in inhibition of signalling via this receptor.
Indeed, as mentioned above, we have previously reported
that EGFR can similarly suppress IGF-IR signalling
through such a mechanism in a tamoxifen-resistant
MCF-7 cell line [29]. A potential consequence of the abil-
ity of HRGb1/erbB3 signalling to suppress IGF-IR signal-
ling activity is that such a mechanism could severely
affect the efficacy of IGF-IR-targeted agents in these
breast cancer cells. Indeed, there is now evidence emer-
ging from experimental breast cancer cell models impli-
cating a role for erbB receptors in resistance to IGF-IR
blockade, with Haluska and colleagues [47] showing that
EGFR/erbB2 signalling can confer resistance to the IGF-
IR tyrosine kinase inhibitor BMS-536924 in MCF-7 cells.
In our present study, a role for erbB3 signalling in resis-
tance to IGF-IR blockade is also clearly implicated, as
HRGb1 readily overcame the growth-inhibitory effects of
the IGF-IR/IR tyrosine kinase inhibitor ABDP in the
MCF-7 and T47D cell lines. ABDP is a novel dual IGF-
IR/IR tyrosine kinase inhibitor that has previously been
reported to potently inhibit IGF-IR signalling in breast
and prostate cancer cell lines [40]. Blockade of IGF-IR
signalling in these cells using ABDP also enhanced
responses to HRGb1 in both cell lines, with phosphoryla-
tion of IRS-1 Y612, Akt and ERK1/2 apparent at lower
concentrations of this ligand and with a greater
magnitude of phosphorylation also observed at the high-
est concentrations of HRGb1 in ABDP-treated compared
to untreated cells. Similar results were observed when
IGF-IR signalling was blocked using an IGF-IR siRNA.
This rapid enhancement of HRGb1 signalling by IGF-IR
inhibition is likely a consequence of two mechanisms.
The first is an IRS-1-mediated mechanism, which immu-
noprecipitation and Western blot analysis revealed a loss
of IRS-1 association with IGF-IR and an increased asso-
ciation of this adaptor protein with erbB3 in MCF-7 and
T47D cells following treatment with ABDP, mirroring
results observed for HRGb1 treatment alone in these cell
types. Thus, HRGb1 signalling was enhanced as a result
of increased availability and association of IRS-1 with
erbB3. This is further supported by the finding that
knockdown of IRS-1 protein levels by siRNA not only
reduced HRGb1-primed Akt phosphorylation but also
prevented the ABDP-induced sensitisation of the cells to
this ligand, greatly reducing signalling via Akt in particu-
lar. The second is that an erbB3-dependent mechanism
appears to play a role, as IGF-IR inhibition by either
ABDP or IGF-IR siRNA knockdown also enhanced
HRGb1-induced erbB3 phosphorylation, with this effect
being most apparent in the MCF-7 cells. The reasons
behind this effect remain unclear, although similar find-
ings have been reported in hepatocellular carcinoma cells
treated with the novel IGF-IR monoclonal antibody
AVE1642 [39]. One possible mechanism was recently
identified by Gijsen and colleagues [48], who reported
that blockade of Akt can activate ADAM17 (ADAM
metallopeptidase domain 17) in erbB2-overexpressing
breast cancer cells, leading to release of heregulins, which
can act in an autocrine manner to activate erbB3. As
IGF-IR blockade can acutely inhibit Akt activity in our
cell lines, such a mechanism may explain the subsequent
phosphorylation of erbB3; however, further studies are
required to confirm this hypothesis. Interestingly, IRS-1
knockdown was not as effective in reducing HRGb1-
induced ERK1/2 activity compared to Akt activity in
ABDP-treated MCF-7 and T47D cell lines. One possible
explanation for this is that the increased erbB3 phosphor-
ylation observed in response to ABDP may provide the
input maintaining ERK1/2 phosphorylation in these cells;
however, further investigation into this mechanism is
required and is currently ongoing.
To determine whether this novel association between
IRS-1 and erbB3 identified in our ER+ cell lines could
also have clinical relevance, an exploratory study was per-
formed in a small series of ER+ clinical breast tumours.
An immunocytochemical assay was developed to detect
phosphorylated IRS-1 Y612 and associations with erbB3,
and other clinical markers were assessed. Importantly, a
significant positive correlation between IRS-1 Y612 phos-
phorylation and total erbB3 expression was observed in
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these ER+ primary breast tumours. As the majority of
these ER+ tumours were found to express low and/or
negative erbB2 levels, these findings directly support our
cell line work and suggest that an association between
erbB3 and IRS-1 may well occur within ER+ breast
tumours. The link between IRS-1 Y612 phosphorylation
levels and Akt activity identified in the cell lines was also
observed in the clinical samples, with significant correla-
tions between phosphorylated levels of IRS-1 Y612 and
Akt in ER+ patients. Moreover, there was a significant
correlation between IRS-1 Y612 and the proliferation
marker Ki-67 in these ER+ tumours, suggesting that the
potential interplay between erbB3, IRS-1 and Akt in
these tumours may culminate in driving cell proliferation.
However, for such signalling to arise, heregulins must be
synthesized and accessible within the cancer milieu.
Importantly, our previous findings based on the same
clinical breast cancer series used in this study, as well as
others [30,49], clearly demonstrate that neuregulins such
as HRGb1 are ubiquitously expressed in clinical breast
tissue, thus making such interplay a distinct possibility
and warranting a more extensive study to be carried out
in a larger breast cancer series. In light of these findings,
the recent suggestion that IRS-1 should be considered as
a biomarker for IGF-IR activity in cancers susceptible to
IGF-IR targeting [50] should be viewed with a degree of
caution, especially in cancer types that also express erbB
receptors and their ligands.
Conclusions
These and previous findings identify IRS-1 as a key signal-
ling component for both IGF-IR and erbB receptor tyro-
sine kinases in ER+ breast cancer cells and as an
important convergence point for cross-talk between these
two receptor tyrosine kinase families. These studies pro-
vide further evidence that this versatile adaptor molecule
may provide an adaptive resistance mechanism when
either of these receptor families is targeted individually.
Consequently, targeting IRS-1 alongside such agents may
prove to be a more effective strategy for the treatment of
ER+ breast cancer, particularly when heregulins are abun-
dant. Although direct targeting of IRS-1 may prove to be
problematic, it may be achievable in ER+ breast cancer
with the use of antihormones, as IRS-1 is an oestrogen-
regulated gene [8]. Indeed, recent reports have provided
evidence that such a therapeutic strategy may prove highly
effective with the IGF-IR inhibitor NVP-AEW541 when
used in combination with an aromatase inhibitor by syner-
gistically inducing apoptosis in aromatase-expressing
MCF-7 and T47D cells in vitro [51] and with a novel anti-
IGF-IR antibody when combined with tamoxifen-suppres-
sing breast tumour cell growth in vivo [52]. However, it
should be noted that it remains to be determined whether
reduced IRS-1 expression is a major contributing factor to
the improved response of the combination treatments uti-
lised in these studies.
Additional material
Additional file 1: Clinicopathological parameters for oestrogen
receptor-positive breast tumour set. Table S1 gives the
clinicopathological parameters of a small historical series of 50 primary
tumours excised from oestrogen receptor-positive (ER+) patients with
histologically proven breast cancer who presented for surgery at the
Nottingham City Hospital. No patient had previously received any form
of adjuvant endocrinological or cytotoxic therapy. EGFR = epidermal
growth factor receptor.
Additional file 2: Effect of insulin-like growth factor receptor
knockdown on heregulin b1 signalling in MCF-7 and T47D cells.
Figure S1 shows the results of Western blot analysis of total insulin-like
growth factor type I receptor (IGF-IR), phosphorylated and total insulin
receptor substrate 1 (IRS-1), erbB3, Akt, ERK1/2 and b-actin protein
expression in MCF-7 and T47D cells following incubation with either lipid
and C si mix (100 nM) or lipid and IGF-IR siRNA (IGF si) mix (100 nM) for
4 days and subsequently challenged with either heregulin b1 (HRGb1)
(10 ng/ml) or vehicle control alone for 5 minutes. Data are representative
of three separate experiments. p-AKT = phosphorylated Akt; pERK1/2 =
phosphorylated extracellular signal-regulated kinase 1/2; c Si = siRNA
control pool.
Abbreviations
ABDP: 4-anilino-5-bromo-2-[4-(2-hydroxy-3-(N, N-dimethylamino)propoxy)
anilino]pyrimidine; BSA: bovine serum albumin; EGFR: epidermal growth
factor receptor; ER: oestrogen receptor; ERK1/2: extracellular signal-regulated
kinase 1/2; FCS: foetal calf serum; HRGβ1: heregulin β1; IGF-IR: insulin-like
growth factor type I receptor; IRS-1: insulin receptor substrate 1; MAPK:
mitogen-activated protein kinase; PBS: phosphate-buffered saline; PI3K:
phosphatidylinositol 3-kinase; RPMI: phenol red-free Roswell Park Memorial
Institute; siRNA: small interfering RNA; TBS: Tris-buffered saline; Y: tyrosine.
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